CTOs on the Move

Intellisphere

www.hcplive.com

 
Intellisphere is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $500M-1 Billion
  • www.hcplive.com
  • 666 Plainsboro Rd
    Plainsboro, NJ USA 08536
  • Phone: 609.716.7777

Executives

Name Title Contact Details

Similar Companies

Barton HealthCare System

The Barton HealthCare System provides a variety of excellent medical services for patients, employees, visitors and the community.

MedImpact

MedImpact Healthcare Systems, Inc. is the nation’s largest privately held pharmacy benefit management (PBM) company, serving health plans, self-funded employers and government entities. Our business model is unique: avoiding conflicts of interest by not dispensing drugs. MedImpact is focused on effectively managing client pharmacy benefits to facilitate better trend management and improved outcomes. We work with clients to direct prescribing to the lowest-net-cost, medically appropriate drug. Our number one goal is client satisfaction by providing flexible solutions and consumer-driven products with a focus on lowest net cost and quality outcomes.

Art and Drama Therapy Institute

Art and Drama Therapy Institute is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.